Core Viewpoint - 康宁杰瑞制药-B (09966) has experienced a significant stock price increase, reflecting positive market sentiment ahead of its upcoming board meeting to approve mid-term results, which are expected to show a profit turnaround [1] Financial Performance - The company anticipates a profit of no less than RMB 20 million for the first half of the year, a notable improvement from a loss of approximately RMB 44.9 million in the same period last year [1] - The turnaround to profitability is attributed to milestone revenues from three authorized collaborations and sales revenue from commercialized products [1] Product Development - 康宁杰瑞制药 has announced that its self-developed PD-L1/integrin αvβ6 bispecific antibody-drug conjugate (ADC) JSKN022 has received formal acceptance for clinical trial application from the China National Medical Products Administration [1] - The company plans to initiate the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors [1] - Currently, there are no marketed ADCs targeting integrin αvβ6 or PD-L1 globally, and related investigational drugs are still in clinical research stages [1]
康宁杰瑞制药-B再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元